Literature DB >> 30995529

Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease.

Mariangela Allocca1, Gionata Fiorino1, Cristiana Bonifacio2, Laurent Peyrin-Biroulet3, Silvio Danese4.   

Abstract

Fibrotic strictures occur in 30% of patients with Crohn's disease (CD). However, there are no therapeutic agents that prevent or reverse fibrotic strictures. Strictures are treated by endoscopic dilatation procedures and surgical procedures, but there are high rates of recurrence. Two antifibrotic agents (nintedanib and pirfenidone) recently were approved for the treatment of idiopathic pulmonary fibrosis and inhibitors of Rho-associated protein kinases 1 and 2 reversed fibrosis in mice with chronic intestinal inflammation. Cross-sectional imaging techniques, such as magnetic resonance (MR) enterography, computed tomography enterography, and bowel ultrasound, are used to assess small-bowel and CD-related complications, including strictures. It is important to be able to determine the degree of inflammation and fibrosis in strictures to select the best therapy; this can be a challenge because inflammation and fibrosis co-exist to varying degrees in a damaged bowel segment. Delayed gadolinium enhancement, magnetization transfer MR imaging, and ultrasound elastography seem to be promising tools for assessing fibrosis in patients with CD. We review noninvasive techniques for fibrosis assessment, including analyses of genetic, epigenetic, and protein markers. We discuss the potential of imaging techniques such as diffusion-weighted and magnetization transfer MR imaging, strain elastography, shear-wave imaging, and positron emission tomography to guide therapeutic decisions for patients with stricturing CD.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CTE; DWI; IBD; MRE; PET

Mesh:

Substances:

Year:  2019        PMID: 30995529     DOI: 10.1016/j.cgh.2019.04.025

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  7 in total

1.  Aptamer-Functionalized Microbubbles Targeted to P-selectin for Ultrasound Molecular Imaging of Murine Bowel Inflammation.

Authors:  Una Goncin; Laura Curiel; C Ronald Geyer; Steven Machtaler
Journal:  Mol Imaging Biol       Date:  2022-07-18       Impact factor: 3.484

Review 2.  Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease.

Authors:  Giorgos Bamias; Theresa T Pizarro; Fabio Cominelli
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 7.290

Review 3.  Revisiting fibrosis in inflammatory bowel disease: the gut thickens.

Authors:  Silvia D'Alessio; Federica Ungaro; Daniele Noviello; Sara Lovisa; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-12-07       Impact factor: 46.802

4.  Localization of recurrent lesions following ileocolic resection for Crohn's disease.

Authors:  Hiroki Ikeuchi; Motoi Uchino; Toshihiro Bando; Yuki Horio; Ryuichi Kuwahara; Tomohiro Minagawa; Yoshiko Goto; Kurando Kusunoki; Masataka Ikeda; Naohito Beppu; Yoshio Takesue
Journal:  BMC Surg       Date:  2021-03-20       Impact factor: 2.102

5.  Ileal Crohn's Disease Exhibits Similar Transmural Fibrosis Irrespective of Phenotype.

Authors:  Helena Tavares de Sousa; Irene Gullo; Claudia Castelli; Cláudia Camila Dias; Florian Rieder; Fátima Carneiro; Fernando Magro
Journal:  Clin Transl Gastroenterol       Date:  2021-04-13       Impact factor: 4.396

Review 6.  Ultrasonography in inflammatory bowel disease - So far we are?

Authors:  Maaser Christian; Maconi Giovanni; Kucharzik Torsten; Allocca Mariangela
Journal:  United European Gastroenterol J       Date:  2022-02-08       Impact factor: 4.623

7.  Pirfenidone Inhibits Cell Proliferation and Collagen I Production of Primary Human Intestinal Fibroblasts.

Authors:  Yingying Cui; Mengfan Zhang; Changsen Leng; Tjasso Blokzijl; Bernadien H Jansen; Gerard Dijkstra; Klaas Nico Faber
Journal:  Cells       Date:  2020-03-22       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.